Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Mecloderm Ointment** is a topical fixed-dose combination of the azole antifungal clotrimazole and the synthetic glucocorticoid betamethasone dipropionate. It is being developed by Dermapharm for moderate to severely inflamed cutaneous candidiasis; the Phase III EU CTIS study compares Mecloderm Ointment with Lotricomb Ointment and vehicle. Clotrimazole inhibits fungal lanosterol 14-alpha demethylase, disrupting ergosterol biosynthesis and fungal cell-membrane integrity, while betamethasone dipropionate activates the glucocorticoid receptor to suppress local inflammatory symptoms such as erythema and pruritus. ([euclinicaltrials.eu](https://euclinicaltrials.eu/search-for-clinical-trials/?EUCT=2022-501415-14-00&lang=en))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clotrimazole + betamethasone dipropionate.